Friday, October 16, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 3, 2026

Credo Technology: High-Speed, High-Stakes AI Infrastructure Play

View original at finance.yahoo.com
Credo Technology: High-Speed, High-Stakes AI Infrastructure Play This article first appeared on GuruFocus…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Rising inventory attributed to scaling up for robust customer forecasts

    80% confidence
  • Credo's solutions typically consume 50% less power than optical alternatives

    80% confidence
  • Nvidia Rubin NVL72 has cable-free tray design

    80% confidence
  • Spending on data center switches in AI back-end networks will push past $100 billion by 2030

    80% confidence
  • Sequential revenue growth expected in mid-single digits for end of fiscal 2026 and into fiscal 2027, leading to more than 200% year-over-year growth in current fiscal year

    80% confidence
  • AECs are engineered to be up to 1,000 times more reliable than optical modules

    80% confidence
  • Scale-up networking market will exceed $40 billion by 2030

    80% confidence
  • Total addressable market has expanded to over $10 billion, more than tripling in just eighteen months

    80% confidence
  • Management sees ALCs eventually surpassing AECs in scope

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com